<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02111057</url>
  </required_header>
  <id_info>
    <org_study_id>2014-233</org_study_id>
    <nct_id>NCT02111057</nct_id>
  </id_info>
  <brief_title>Perioperative Flare in RA: Characterization of Clinical and Biological Features</brief_title>
  <official_title>Perioperative Flare in RA: Characterization of Clinical and Biological Features</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers at the Hospital for Special Surgery are trying to learn more about post-operative&#xD;
      rheumatoid arthritis flare (RA). This study hopes to understand RA flare after total joint&#xD;
      replacement surgery and what the result of flaring is for patients over the 6 weeks post&#xD;
      operation.&#xD;
&#xD;
      Through this study we aim to describe rates, characteristics, and risk factors of RA flare&#xD;
      within 6 weeks of total hip arthroplasty (THA) and total knee arthroplasty (TKA)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The condition to be studied is worsening (flare) of rheumatoid arthritis (RA) in patients who&#xD;
      have undergone arthroplasty. RA patients were recruited prior to elective THA and TKA and&#xD;
      prospectively followed. Clinicians evaluated RA clinical characteristics 0-2 weeks before and&#xD;
      6 weeks post surgery. Patients answered questions regarding disease activity including&#xD;
      self-reported joint counts and flare status weekly for 6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 16, 2013</start_date>
  <completion_date type="Actual">May 9, 2017</completion_date>
  <primary_completion_date type="Actual">May 9, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of RA Flare at 6 week post surgery</measure>
    <time_frame>6 weeks</time_frame>
    <description>The primary outcome is the rate of RA flare within 6 weeks of surgery as measured by the Outcome Measures in Rheumatoid Arthritis Clinical Trials(OMERACT) flare questionnaire. For comparison, the rate of RA flare at 1 week post surgery is measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity and impact of flares 6 weeks and one year post arthroplasty, using the OMERACT PFQs</measure>
    <time_frame>6 weeks and one year</time_frame>
    <description>The OMERACT PFQs include flare intensity, duration of flare, worsening of domains associated with flare (pain, fatigue, stiffness, patient reported tender and swollen joint count, difficulties with coping and participation).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">162</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Perioperative RA</arm_group_label>
    <description>Patients with Rheumatoid Arthritis undergoing a primary or secondary total hip replacement, between the ages of 18 and 90.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      During surgery, the subjects' surgeon will take samples of the tissue removed as part of&#xD;
      their surgery from their joint. Specifically for Total Hip Replacement (THR), the femoral&#xD;
      head will be collected intraoperatively from standardized anatomic sites, (fovea and capsular&#xD;
      reflection). For Total Knee replacement (TKR), tissue samples of the patella cartilage,&#xD;
      distal femur and proximal tibia, and synovium from the suprapatellar pouch will be collected&#xD;
      intraoperatively.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will comprise of roughly 200 patients with Rheumatoid Arthritis&#xD;
        undergoing a total joint replacement.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;18&#xD;
&#xD;
          2. Patients with Rheumatoid Arthritis undergoing total joint replacement surgery&#xD;
&#xD;
          3. Satisfy American College of Rheumatology(ACR)/European League Against&#xD;
             Rheumatism(EULAR) 2010 classification criteria and/or the 1987 RA criteria (see below)&#xD;
             and be diagnosed with RA&#xD;
&#xD;
          4. For control subjects: Have OA(Osteoarthritis), SLE(Systemic lupus erythematosus) or&#xD;
             other inflammatory arthritis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of any other systemic rheumatic disease&#xD;
&#xD;
          2. Diagnosis of or crystalline arthropathy.&#xD;
&#xD;
          3. Unable to understand or read English.&#xD;
&#xD;
          4. Unable to follow the study protocol in a reliable manner.&#xD;
&#xD;
          5. Age &lt; 18 or &gt;75.&#xD;
&#xD;
        EXPLANATION OF CRITERIA:&#xD;
&#xD;
        Rheumatoid arthritis 1987 criteria:&#xD;
&#xD;
          1. morning stiffness in and around joints lasting at least 1 hour before maximal&#xD;
             improvement;&#xD;
&#xD;
          2. soft tissue swelling (arthritis) of 3 or more joint areas observed by a physician;&#xD;
&#xD;
          3. swelling (arthritis) of the proximal interphalangeal, metacarpophalangeal, or wrist&#xD;
             joints;&#xD;
&#xD;
          4. symmetric swelling (arthritis);&#xD;
&#xD;
          5. rheumatoid nodules;&#xD;
&#xD;
          6. the presence of rheumatoid factor; and&#xD;
&#xD;
          7. radiographic erosions and/or periarticular osteopenia in hand and/or wrist joints.&#xD;
&#xD;
               -  Criteria 1 through 4 must have been present for at least 6 weeks. Rheumatoid&#xD;
                  arthritis is defined by the presence of 4 or more criteria, and no further&#xD;
                  qualifications (classic, definite, or probable) or list of exclusions are&#xD;
                  required.&#xD;
&#xD;
        ACR/EULAR 2010 criteria for the classification of RA:&#xD;
&#xD;
        Table 3. The 2010 American College of Rheumatology/European League Against Rheumatism&#xD;
        classification criteria for rheumatoid arthritis&#xD;
&#xD;
        Target population (Who should be tested?): Patients who&#xD;
&#xD;
          1. have at least 1 joint with definite clinical synovitis (swelling)*&#xD;
&#xD;
          2. with the synovitis not better explained by another disease&#xD;
&#xD;
        Classification criteria for RA (score-based algorithm: add score of categories A-D;&#xD;
&#xD;
        a score of â‰¥6/10 is needed for classification of a patient as having definite RA&#xD;
&#xD;
        Score&#xD;
&#xD;
        A. Joint involvement&#xD;
&#xD;
        1 large joint 0&#xD;
&#xD;
        2-10 large joints 1&#xD;
&#xD;
        1-3 small joints (with or without involvement of large joints) 2&#xD;
&#xD;
        4-10 small joints (with or without involvement of large joints) 3&#xD;
&#xD;
        &gt;10 joints (at least 1 small joint) 5&#xD;
&#xD;
        B. Serology (at least 1 test result is needed for classification)&#xD;
&#xD;
        Negative RF and negative ACPA 0&#xD;
&#xD;
        Low-positive RF or low-positive ACPA 2&#xD;
&#xD;
        High-positive RF or high-positive ACPA 3&#xD;
&#xD;
        C. Acute-phase reactants (at least 1 test result is needed for classification)&#xD;
&#xD;
        Normal CRP and normal ESR 0&#xD;
&#xD;
        Abnormal CRP or abnormal ESR 1&#xD;
&#xD;
        D. Duration of symptoms&#xD;
&#xD;
        &lt; 6 weeks 0&#xD;
&#xD;
          -  6 weeks 1&#xD;
&#xD;
               -  The criteria are aimed at classification of newly presenting patients. In&#xD;
                  addition, patients with erosive disease typical of rheumatoid arthritis (RA) with&#xD;
                  a history compatible with prior fulfillment of the 2010 criteria should be&#xD;
                  classified as having RA. Patients with longstanding disease, including those&#xD;
                  whose disease is inactive (with or without treatment) who, based on&#xD;
                  retrospectively available data, have previously fulfilled the 2010 criteria&#xD;
                  should be classified as having RA.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hss.edu/</url>
    <description>Hospital for Special Surgery</description>
  </link>
  <link>
    <url>http://www.hss.edu/physicians_goodman-susan.asp</url>
    <description>Principal Investigator, Susan Goodman MD</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2014</study_first_posted>
  <last_update_submitted>October 16, 2019</last_update_submitted>
  <last_update_submitted_qc>October 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Total Hip Replacement</keyword>
  <keyword>Flare</keyword>
  <keyword>Perioperative Outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 2, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02111057/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 9, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02111057/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

